#ALLO Allogene Therapeutics' ALLO-329
The FDA has cleared the Investigational New Drug (IND) application for ALLO-329, a dual-targeted CD19/CD70 allogeneic CAR T cell therapy, to treat autoimmune diseases. This marks a significant milestone in the company's efforts to address unmet medical needs.
ALLO-316 for Renal Cell Carcinoma*: Allogene Therapeutics presented updated data from its Phase 1 TRAVERSE study of ALLO-316, showing a 31% confirmed response rate among patients with high levels of CD70.
Mainnet Launch and Core Protocol*: Allora's mainnet introduced a decentralized Model Coordination Network (MCN), enabling real-time collaboration between AI/ML models.
Token Price and Market Performance*: Allo's token price is currently $0.003345, with a 7.78% increase in the past 24 hours.
- *Website Performance Upgrade*: Allo upgraded its website infrastructure in July 2025 to reduce latency and improve responsiveness, particularly for real-time trading of tokenized assets.
- *AlloX Protocol Expansion*: AlloX added support for fractional ownership of tokenized stocks in May 2025, leveraging Binance Smart Chain's low fees ¹ ² ³.$SOL $BNB $ETH